ID: ALA2425648

Max Phase: Preclinical

Molecular Formula: C17H19N5O

Molecular Weight: 309.37

Molecule Type: Small molecule

Representations

Canonical SMILES:  O[C@H]1CC[C@H](Nc2nccc(-c3cnc4ccccn34)n2)CC1

Standard InChI:  InChI=1S/C17H19N5O/c23-13-6-4-12(5-7-13)20-17-18-9-8-14(21-17)15-11-19-16-3-1-2-10-22(15)16/h1-3,8-13,23H,4-7H2,(H,18,20,21)/t12-,13-

Standard InChI Key:  RPBRKXHDLFDUJN-JOCQHMNTSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 309.37

Molecular Weight (Monoisotopic): 309.1590

AlogP: 2.51

#Rotatable Bonds: 3

Polar Surface Area: 75.34

Molecular Species: NEUTRAL

HBA: 6

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 5.27

CX LogP: 1.35

CX LogD: 1.35

Aromatic Rings: 3

Heavy Atoms: 23

QED Weighted: 0.78

Np Likeness Score: -1.44

References

1. Palmer WS, Alam M, Arzeno HB, Chang KC, Dunn JP, Goldstein DM, Gong L, Goyal B, Hermann JC, Hogg JH, Hsieh G, Jahangir A, Janson C, Jin S, Ursula Kammlott R, Kuglstatter A, Lukacs C, Michoud C, Niu L, Reuter DC, Shao A, Silva T, Trejo-Martin TA, Stein K, Tan YC, Tivitmahaisoon P, Tran P, Wagner P, Weller P, Wu SY..  (2013)  Development of amino-pyrimidine inhibitors of c-Jun N-terminal kinase (JNK): kinase profiling guided optimization of a 1,2,3-benzotriazole lead.,  23  (5): [PMID:23352510] [10.1016/j.bmcl.2012.12.047]

2.  (2013)  JNK modulators, 

Source

Source(2):

• Scientific Literature
• BindingDB Database